Janux Therapeutics designates Zachariah McIver as Vice President, Clinical Development
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, yesterday announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years […]
